Literature DB >> 12714322

Oxidative capacity in failing hearts.

Guangrong Gong1, Jingbo Liu, Peihua Liang, Tao Guo, Qingsong Hu, Ko Ochiai, Mingxiao Hou, Yun Ye, Xiaoyun Wu, Abdul Mansoor, Arthur H L From, Kamil Ugurbil, Robert J Bache, Jianyi Zhang.   

Abstract

Although high-energy phosphate metabolism is abnormal in failing hearts [congestive heart failure (CHF)], it is unclear whether oxidative capacity is impaired. This study used the mitochondrial uncoupling agent 2,4-dinitrophenol (DNP) to determine whether reserve oxidative capacity exists during the high workload produced by catecholamine infusion in hypertrophied and failing hearts. Left ventricular hypertrophy (LVH) was produced by ascending aortic banding in 21 swine; 9 animals developed CHF. Basal myocardial phosphocreatine (PCr)/ATP measured with 31P NMR spectroscopy was decreased in both LVH and CHF hearts (corresponding to an increase in free [ADP]), whereas ATP was decreased in hearts with CHF. Infusion of dobutamine and dopamine (each 20 microg. kg-1. min-1 iv) caused an approximate doubling of myocardial oxygen consumption (MVO2) in all groups and decreased PCr/ATP in the normal and LVH groups. During continuing catecholamine infusion, DNP (2-8 mg/kg iv) caused further increases of MVO2 in normal and LVH hearts with no change in PCr/ATP. In contrast, DNP caused no increase in MVO2 in the failing hearts; the associated decrease of PCr/ATP suggests that DNP decreased the mitochondrial proton gradient, thereby causing ADP to increase to maintain adequate ATP synthesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12714322     DOI: 10.1152/ajpheart.01142.2002

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  56 in total

Review 1.  Mitochondria in heart failure.

Authors:  Mariana G Rosca; Charles L Hoppel
Journal:  Cardiovasc Res       Date:  2010-07-28       Impact factor: 10.787

2.  Relationships between regional myocardial wall stress and bioenergetics in hearts with left ventricular hypertrophy.

Authors:  Julia Feygin; Qinsong Hu; Cory Swingen; Jianyi Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-03-07       Impact factor: 4.733

Review 3.  New aspects of impaired mitochondrial function in heart failure.

Authors:  Mariana G Rosca; Charles L Hoppel
Journal:  J Bioenerg Biomembr       Date:  2009-04       Impact factor: 2.945

4.  Experimentally observed phenomena on cardiac energetics in heart failure emerge from simulations of cardiac metabolism.

Authors:  Fan Wu; Jianyi Zhang; Daniel A Beard
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-08       Impact factor: 11.205

Review 5.  Energy metabolism in heart failure and remodelling.

Authors:  Joanne S Ingwall
Journal:  Cardiovasc Res       Date:  2008-11-05       Impact factor: 10.787

6.  Dietary fat supply to failing hearts determines dynamic lipid signaling for nuclear receptor activation and oxidation of stored triglyceride.

Authors:  Ryan Lahey; Xuerong Wang; Andrew N Carley; E Douglas Lewandowski
Journal:  Circulation       Date:  2014-09-29       Impact factor: 29.690

Review 7.  Integration of cellular bioenergetics with mitochondrial quality control and autophagy.

Authors:  Bradford G Hill; Gloria A Benavides; Jack R Lancaster; Scott Ballinger; Lou Dell'Italia; Zhang Jianhua; Victor M Darley-Usmar
Journal:  Biol Chem       Date:  2012-12       Impact factor: 3.915

Review 8.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

9.  Creatine and phosphate pools are maintained at energetically optimal levels in the heart during hypertrophic remodeling and heart failure.

Authors:  Daniel A Beard; Fan Wu
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2009

10.  Strong inference for systems biology.

Authors:  Daniel A Beard; Martin J Kushmerick
Journal:  PLoS Comput Biol       Date:  2009-08-28       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.